| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/26/2013 | US20130251818 Personal lubricants |
| 09/26/2013 | US20130251812 Sequestered antagonist formulations |
| 09/26/2013 | US20130251790 Low Dose Pharmaceutical Composition Comprising Zanamivir |
| 09/26/2013 | US20130251789 Tamper-resistant oral opioid agonist formulations |
| 09/26/2013 | US20130251787 Treatment of Pulmonary Hypertension with Leukotriene Inhibitors |
| 09/26/2013 | US20130251781 Composition and Method for Treating Connective Tissue Damage |
| 09/26/2013 | US20130251763 Transdermal compositions |
| 09/26/2013 | US20130251761 Organic compounds |
| 09/26/2013 | US20130251760 Transdermal Analgesic Systems with Reduced Abuse Potential |
| 09/26/2013 | US20130251733 Anti-cxcr3 antibodies |
| 09/26/2013 | US20130251730 Compounds and Mixtures Influencing Inflammatory States |
| 09/26/2013 | US20130251728 Method of Treating Stress Hyperglycemia with Human Antibodies to the Glucagon Receptor |
| 09/26/2013 | US20130251727 Egfr-based peptides |
| 09/26/2013 | US20130251726 Novel hiv -1 broadly neutralizing antibodies |
| 09/26/2013 | US20130251709 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of acute myelogenous leukemia |
| 09/26/2013 | US20130251705 Compositions and methods for diagnosing and treating cancer |
| 09/26/2013 | US20130251703 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 |
| 09/26/2013 | US20130251689 Keratin compositions for treatment of bone deficiency or injury |
| 09/26/2013 | US20130251685 Injectable Cross-Linked Polymeric Preparations and Uses Thereof |
| 09/26/2013 | US20130251673 Hepatitis b antiviral agents |
| 09/26/2013 | US20130251668 Use of osteoprotegerin (opg) to increase human pancreatic beta cell survival and proliferation |
| 09/26/2013 | US20130251664 1L1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target |
| 09/26/2013 | US20130251651 Fetal Skin Cell Protein Compositions For The Treatment Of Skin Conditions, Disorders Or Diseases And Methods Of Making And Using The Same |
| 09/26/2013 | US20130251635 High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders |
| 09/26/2013 | US20130251634 Methods and compositions for protection of cells and tissues from computed tomography radiation |
| 09/26/2013 | US20130248448 Citrate-Based Dialysate Chemical Formulations |
| 09/25/2013 | EP2641968A2 Orally administered pharmaceutical composition and preparation method thereof, for the prevention and treatment of irritable bowel syndrome, comprising an intestinal motility modifier and -d-galactosidase |
| 09/25/2013 | EP2641918A2 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
| 09/25/2013 | EP2641917A2 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
| 09/25/2013 | EP2641614A1 Pharmaceutical preparation integrated with microneedles for skin treatment |
| 09/25/2013 | EP2641608A2 Products and methods using soy peptides to lower total and LDL cholesterol levels |
| 09/25/2013 | EP2641602A1 Method for treating gynecological diseases |
| 09/25/2013 | EP2641601A1 Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezimob |
| 09/25/2013 | EP2641600A1 Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies |
| 09/25/2013 | EP2640720A2 Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| 09/25/2013 | EP2640468A1 Method of administration and treatment |
| 09/25/2013 | EP2640412A1 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer |
| 09/25/2013 | EP2640410A1 Composition comprising a peptide and an inhibitor of viral neuraminidase |
| 09/25/2013 | EP2640392A2 Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
| 09/25/2013 | EP2640387A1 Method of treatment with braf inhibitor |
| 09/25/2013 | EP2640386A1 Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
| 09/25/2013 | EP2640379A2 Low dose cannabinoid medicaments |
| 09/25/2013 | EP2640377A1 Fgfr1 extracellular domain combination therapies |
| 09/25/2013 | CN103328626A Cancer stem cell mass and process for production thereof |
| 09/25/2013 | CN103327975A Combinations comprising macitentan for the treatment of glioblastoma multiforme |
| 09/25/2013 | CN103319579A Protein AFLA-216 associated with azole drug sensitivity in aspergillus flavus as well as encoding gene and application thereof |
| 09/25/2013 | CN103319554A Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 09/25/2013 | CN103316352A Graphene oxide nano-drug carrier and anti-tumor drug as well as preparation method of anti-tumor drug |
| 09/25/2013 | CN103316348A New use of 5-HT2A receptor stimulant |
| 09/25/2013 | CN103316347A Application of micro nucleotide and antagonist or simulator thereof in preparation of medicines for preventing myocardial damage and fibrosis |
| 09/25/2013 | CN103316346A Pharmaceutical composition for treating epilepsy |
| 09/25/2013 | CN103316345A Use melanocortins to treat insulin sensitivity |
| 09/25/2013 | CN103316344A EGFR-TKI compound for delaying or reversing drug-resistance in lung cancer treatment, and preparation thereof |
| 09/25/2013 | CN103316343A Application of biguanide based medicament in medicaments for delaying or reversing acquired drug-resistance of NSELC treated by EGFR-TKI |
| 09/25/2013 | CN103316342A Applications of miR-31 inhibitor in inhibition of angiostenosis after damage |
| 09/25/2013 | CN103316338A Health-care immunization needle injection method of piglet |
| 09/25/2013 | CN103316333A Recombinant human lysozyme with broad-spectrum tumor cell killing activity and its application |
| 09/25/2013 | CN103316326A Pharmaceutical cyclosporin composition |
| 09/25/2013 | CN103316038A Pyruvate oral rehydration salt composition for curing circulation hypovolemia or water-losing with salt-losing |
| 09/25/2013 | CN103315944A Methods and devices for lymphatic targeting |
| 09/25/2013 | CN102784395B Application of MAPK-ERK1/2 signal channel inhibitor to preparation of double-minute medicine for removing or inhibiting tumor cells |
| 09/25/2013 | CN102626401B Hydrogel paste and preparation method thereof |
| 09/25/2013 | CN102397304B Application of Chinese herbal medicine ginkgo biloba extract in preparation of medicament for reducing weight and lipid or preparation of medicament with lipase activity inhibitory action |
| 09/25/2013 | CN102349873B Pharmaceutical compositions based on idazoxan salt or one of polymorphs thereof |
| 09/25/2013 | CN102145011B Composition for preventing and curing diarrhea, preparation method and application of composition |
| 09/24/2013 | US8541392 Polymer controlled induced viscosity fiber system and uses thereof |
| 09/24/2013 | US8541376 Composition comprising and method of using angiopoietin-like protein 3 ANGPTL3 |
| 09/24/2013 | US8541023 Immunogenic compositions containing phospholipid |
| 09/24/2013 | US8541017 Use of alginate matrices to control cell growth |
| 09/24/2013 | CA2770851C Blockade of t lymphocyte down-regulation associated with ctla-4 signaling |
| 09/24/2013 | CA2595517C Drug carrier and drug carrier kit for inhibiting fibrosis |
| 09/24/2013 | CA2562235C Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| 09/24/2013 | CA2542691C Il-6 antagonist for use as mesothelioma therapeutic agent |
| 09/24/2013 | CA2539567C Nutritional and therapeutic compositions to increase bodily glutathione levels |
| 09/24/2013 | CA2533730C Methods for treatment of dermatological conditions |
| 09/24/2013 | CA2489090C Nutritional composition for detoxification and cancer prevention |
| 09/24/2013 | CA2486583C Marker molecules associated with lung tumors |
| 09/24/2013 | CA2448427C Molecules and methods for inhibiting shedding of kim-1 |
| 09/24/2013 | CA2443294C Remedies for infant chronic arthritis-relating diseases |
| 09/24/2013 | CA2434760C Differentiated cells suitable for human therapy |
| 09/19/2013 | WO2013137396A1 NOVEL INTEGRIN α9β1 LIGAND AND USES THEREOF |
| 09/19/2013 | WO2013137328A1 Method for screening anticancer drugs, and anticancer drug that induces cell death and uses substance that increases granzyme m activity as active ingredient |
| 09/19/2013 | WO2013135880A1 Combination of a mc1r receptor agonist and uvb for the treatment and/or prevention of pigmentation disorders |
| 09/19/2013 | WO2012135970A8 Inhibitors of phosphatidic acid phosphohydrolase (pap), including d-propranolol and analogs thereof, alone or in combination with desipramine, for the treatment of cancers that depend on the epidermal growth factor receptor (egfr), oncogenic variants thereof and other members of the erbb/her family |
| 09/19/2013 | US20130245355 3-hetaryl-substituted pyrrolo[2,3 b]pyridine derivatives as pdk1 inhibitors |
| 09/19/2013 | US20130245231 Pharmaceutical composition for the treatment of dry eye |
| 09/19/2013 | US20130245226 Antibodies To Non-Functional P2X7 Receptor |
| 09/19/2013 | US20130245126 Geranylgeranylacetone formulations and retinal delivery thereof |
| 09/19/2013 | US20130245097 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 09/19/2013 | US20130245080 Benzothiazolone compound |
| 09/19/2013 | US20130245074 Novel compound and medical use thereof |
| 09/19/2013 | US20130245068 Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases |
| 09/19/2013 | US20130245049 Novel Antiviral Compounds |
| 09/19/2013 | US20130245044 Triazolo[4, 5-d] pyramidine derivatives and their use as purine receptor antagonists |
| 09/19/2013 | US20130245040 Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| 09/19/2013 | US20130245037 Stabilization of Hypoxia Inducible Factor (HIF) Alpha |
| 09/19/2013 | US20130245034 Inhibitors Of Histone Deacetylase |
| 09/19/2013 | US20130245031 Fused heteroaromatic pyrrolidinones |
| 09/19/2013 | US20130245014 Jak kinase modulating compounds and methods of use thereof |
| 09/19/2013 | US20130245011 Modulators of ATP-Binding Cassette Transporters |